Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict who will thrive with brain stimulation for Parkinson's?

NCT ID NCT02360683

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 700 Parkinson's patients who received deep brain stimulation to see which factors predict a meaningful improvement in quality of life after 1, 3, and 5 years. Researchers analyzed clinical, imaging, and genetic data to identify who benefits most. The goal is to personalize treatment decisions and avoid unnecessary risks or costs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
deep brain stimulation (subthalamic nucleus)
What this could lead to
If successful, this could help doctors better select which Parkinson's patients will benefit most from deep brain stimulation, improving outcomes and reducing unnecessary risks.
What could go wrong
This is an observational analysis of existing data, not a new treatment trial. It may not identify clear predictors, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

700 people

The number who actually took part.

Started

Nov 2013

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Multicentric French cohort of 1000 Parkinson's disease patients, for obtain 400 patients in the failure group

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients receiving a pre- therapeutic assessment and therapeutic monitoring for one year , 3 years and 5 years as part of the regular monitoring of the subthalamic stimulation * Bilateral STN stimulation considered * Patient able to provide their free and informed consent * Patient with insurance coverage Exclusion Criteria: * Atypical Parkinson's disease do not meet the criteria of stuff . * MP under 5 years * Severe cognitive impairment or dementia ( Score Moca \<24 and DSM-IV criteria) * Parkinson's Psychosis * Reply to L- dopa \<30 % * Against indication for surgery * Severe brain atrophy or abnormal MRI * The presence of another very serious condition terminal life- short-term prognosis ( malignancy ) is an indication against .

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson's disease

Contacts and locations

Locations

  • CHU Hôpital NORD

    Amiens, France

  • CHU Hôpital Pontchaillou

    Rennes, France

  • CHU Purpan

    Toulouse, France

  • CHU de Poitiers

    Poitiers, France

  • CHU hôpital Nord Laennec

    Nantes, France

  • Chu Ch.Nicolle

    Rouen, France

  • Chu Gabriel-Montpied

    Clermont-Ferrand, France

  • Devos

    Lille, 59037, France

  • Fondation Ophtalmologique Adolphe de Rothschild

    Paris, France

  • Hopital Pitie Salpetriere

    Paris, France

  • Hôpital Central,

    Nancy, France

  • Hôpital Pasteur

    Nice, France

  • Hôpital Pierre Wertheimer

    Bron, France

  • Hôpital de Hautepierre

    Strasbourg, France

  • Hôpital de la Timone

    Marseille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.